4th September 2023

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release - Cipla Medpro South Africa (Pty) Ltd., a wholly owned subsidiary of the Company in South Africa to acquire Actor Pharma (Pty) Ltd., South Africa

Dear Sir/Madam,

Please find enclosed press release dated 4th September 2023 on the captioned subject.

This is for your information and records.

Thanking you,
Yours faithfully,
For Cipla Limited

RAJENDRA KUMAR CHOPRA
Company Secretary

Prepared by: Mandar Kurghode
PRESS RELEASE

Cipla Medpro South Africa (Pty) Ltd (“Cipla South Africa”) to acquire Actor Pharma (Pty) Ltd.
Strengthens its over-the-counter product portfolio

South Africa | India 4 September 2023: Cipla South Africa, a 100% owned subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”) signed a binding term sheet with Actor Holdings (Pty) Limited to acquire 100% of the issued ordinary shares of Actor Pharma (Pty) Limited (“Actor”). This development underpins Cipla’s commitment and investment in its over the counter (OTC) business and supports its journey to be a leading healthcare player in South Africa. This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities and leverage cost synergies in the South African market.

Actor was founded in 2009 and has quickly grown to become the 5th largest, privately owned, OTC player in the South African private market. Actor specializes in OTC and generic medicine, where they have established strong consumer brands, and identified niche prescription markets in categories of Women’s health, Nasal, Cough & Cold and Baby & Child. In addition, Actor has an exciting and innovative pipeline and in its last financial year (FY23) delivered revenue of R234 million, on the back of strong double-digit growth.

Commenting on the acquisition, Umang Vohra, Global MD & CEO, Cipla Limited said, “This is in line with our strategy of strengthening our OTC and wellness portfolio. We believe this is an excellent opportunity to leverage our existing marketing capabilities, unlock future growth opportunities and optimize the performance of our pipeline”.

Paul Miller, CEO, Cipla South Africa said, “This is a unique opportunity that helps to build Cipla’s OTC portfolio, providing the business with a more balanced revenue contribution between the prescription and over-the-counter business and continue to provide additional quality medicines for consumers”.

Lynton Lomas, shareholder of Actor said, “We are delighted to transact with a company of Cipla’s stature. With the focussed approach of their commercial team, we are excited to see Actor grow from strength to strength in future”.

The transaction is expected to close in the next three to four months, subject to the negotiation and signing of the definitive transaction agreements (which are expected to be concluded imminently) as well as receiving regulatory approval from South Africa’s Competition Commission.

About Cipla South Africa

Cipla Medpro South Africa (Pty) Limited (‘Cipla South Africa’) is a wholly owned subsidiary of Cipla Limited, India (‘Cipla’) and 3rd largest pharmaceutical company in South Africa (and 2nd largest in the Rx sector). Through Cipla’s ethos of ‘Caring for Life’, Cipla South Africa produces world-class medicines at affordable prices for the public and private sectors, advancing healthcare for all South Africans.

For more information, visit www.cipla.co.za
About Cipla
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 86 markets. Cipla is the 3rd largest in pharma in India (IQVIA MAT July’23), 3rd largest pharmaceutical company in South Africa (and 2nd largest in the Rx sector) (IQVIA MAT July’23), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders.

For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact:

**Corporate Communications**
Heena Kanal
E-Mail: CorpComm@cipla.com

**Investor Relations**
Ajinkya Pandharkar
E-Mail: Investor.Relations@cipla.com